Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector.
Fredric P Manfredsson1, Corinna Burger, Aaron C Rising
1Department of Neuroscience, Powell Gene Therapy Center, McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, Florida 32611, USA.
This study shows a new way to control Glial cell line-derived neurotrophic factor (GDNF) gene therapy for Parkinson's disease using a doxycycline-inducible system. This offers safer, long-term GDNF expression for potential Parkinson's treatments.
Area of Science:
- Neuroscience
- Gene Therapy
- Molecular Biology
Background:
- Glial cell line-derived neurotrophic factor (GDNF) gene transfer shows promise for Parkinson's disease (PD) treatment.
- External regulation of transgene expression is crucial for enhancing the safety of GDNF gene therapy strategies.
- Controlling GDNF expression levels is essential to balance therapeutic efficacy and potential side effects.
Purpose of the Study:
- To develop a system for dynamic, long-term control of GDNF expression using a recombinant adeno-associated virus (rAAV) vector.
- To assess the sensitivity of GDNF expression to doxycycline (DOX) and its impact on efficacy and side effects.
- To evaluate the safety profile of intrastriatal vector delivery for GDNF gene therapy in Parkinson's disease models.
Main Methods:
- Utilized a recombinant adeno-associated virus (rAAV)-based bicistronic tetracycline (tet)-off construct for GDNF gene transfer.
- Employed nigrostriatal GDNF overexpression in rodents, monitoring body weight alterations for longitudinal in vivo tracking.
- Administered dietary doxycycline (DOX) to regulate GDNF expression and measured striatal GDNF levels.
Main Results:
- Achieved dynamic, long-term control of GDNF expression, highly sensitive to dietary doxycycline levels.
- Undetectable striatal GDNF levels were observed at serum DOX levels below those with antimicrobial activity.
- In the absence of DOX, striatal GDNF levels exceeded those required for PD model efficacy, and no significant GDNF-associated side effects were noted with intrastriatal delivery.
Conclusions:
- The developed single rAAV vector system provides sensitive, doxycycline-regulated GDNF expression for potential Parkinson's disease therapy.
- This system demonstrates effective control over GDNF levels, mitigating risks associated with uncontrolled overexpression.
- The findings support the utility of this rAAV vector as an experimental reagent for PD treatment development.
More Related Videos
07:27Targeting the Corticospinal Tract in Neonatal Rats with a Double-Viral Vector using Combined Brain and Spine Surgery
Published on: June 30, 2021
08:52Convection Enhanced Delivery of Optogenetic Adeno-associated Viral Vector to the Cortex of Rhesus Macaque Under Guidance of Online MRI Images
Published on: May 23, 2019